Neuland Laboratories Ltd.
NSE: NEULANDLAB | BSE: 524558
₹18,944.00
₹-44.00
(-0.23%)
As on 03-Jul-2026IST
Market cap
₹24,270 Cr
Revenue (TTM)
₹2,023 Cr
P/E Ratio
66.7
P/B Ratio
13
Div. Yield
0.2 %
Quality Score
8/10
Growth Score
8/10
Valuation Score
2/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹364 Cr
-
ROE
18.5 %
-
ROCE
23.5 %
-
Industry P/E
51.33
-
EV/EBITDA
39.9
-
Debt to Equity
0.1
-
Book Value
₹1460.3
-
EPS
₹283.7
-
Face value
10
-
Shares outstanding
12,829,889
10 Years Aggregate
CFO
₹1,287.55 Cr
EBITDA
₹1,744.60 Cr
Net Profit
₹986.82 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| 24.8 | 12.0 | 52.4 | 58.1 | 88.4 | 53.8 | 35.8 |
|
BSE Sensex
| -8.2 | 4.2 | 6.1 | -6.8 | 6.3 | 8.2 | 11.1 |
|
BSE Healthcare
| 15.3 | 8.2 | 21.1 | 13.1 | 24.7 | 14.0 | 12.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| 6.2 | 159.8 | 217.4 | 7.9 | 41.7 | 161.5 | -12.2 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsNews & Analysis
All News
1 min read•By Research Desk
About Neuland Lab
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics,... cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
-
Incorporated
1984
-
Chairman
Davuluri Rama Mohan Rao
-
Managing Director
Davuluri Saharsh Rao
-
Headquarters
Hyderabad, Telangana
-
Website
Looking for more details about Neuland Laboratories Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Neuland Lab
What is the current share price of Neuland Laboratories Ltd Today?
The share price of Neuland Laboratories Ltd is ₹18,944.00 (NSE) and ₹18,916.45 (BSE) as of 03-Jul-2026 IST. Neuland Laboratories Ltd has given a return of 88.45% in the last 3 years.
What is the current PB & PE ratio of Neuland Laboratories Ltd?
The P/E ratio of Neuland Laboratories Ltd is 66.68 times as on 03-Jul-2026, a 30 premium to its peers’ median range of 51.33 times.
The P/B ratio of Neuland Laboratories Ltd is 12.95 times as on 03-Jul-2026, a 244 premium to its peers’ median range of 3.77 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
59.57
|
10.17
|
|
2024
|
26.86
|
6.29
|
|
2023
|
14.12
|
2.32
|
|
2022
|
20.64
|
1.57
|
|
2021
|
33.22
|
3.41
|
What is the 52 Week High and Low of Neuland Laboratories Ltd?
The 52-week high and low of Neuland Laboratories Ltd are Rs 19,747.00 and Rs 11,500.00 as of 06-Jul-2026.
What is the market cap of Neuland Laboratories Ltd?
Neuland Laboratories Ltd has a market capitalisation of ₹ 24,270 Cr as on 03-Jul-2026. As per SEBI classification, it is a company.
Should I invest in Neuland Laboratories Ltd?
Before investing in Neuland Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.